Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Completed · Phase 3

Conditions studied: Open-Angle Glaucoma, Ocular Hypertension

In brief

This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.

Key facts

Study ID

NCT03850782

Run by

AbbVie

People needed

515

Starts

2019-02-28

Expected to finish

2025-08-08

Last updated by the study team

2025-08-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of either open angle glaucoma (OAG) (i.e., primary OAG, pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring intraocular pressure-lowering treatment.

You may not qualify if…

• Concurrent or anticipated enrollment in another investigational drug or device study or participation in such a study within 2 months prior to enrolling in this study.
• Previous administration with Bimatoprost SR in the study eye.

Where it is running

• Atlantis Eye Care /ID# 235530 — Huntington Beach, California, United States
• Lakeside Vision Center /ID# 234970 — Irvine, California, United States
• Global Research Foundation /ID# 237350 — Los Angeles, California, United States
• The Eye Research Foundation /ID# 234521 — Newport Beach, California, United States
• Byers Eye Institute Stanford /ID# 235544 — Palo Alto, California, United States
• Foothill Eye Institute /ID# 235640 — Pasadena, California, United States
• Connecticut Eye Consultants P.C. /ID# 234981 — Danbury, Connecticut, United States
• Advanced Research, LLC /ID# 236045 — Deerfield Beach, Florida, United States
• Segal Drug Trials, Inc /ID# 235784 — Delray Beach, Florida, United States
• International Research Center /ID# 238050 — Tampa, Florida, United States
• Thomas Eye Group PC /ID# 235737 — Sandy Springs, Georgia, United States
• Indiana University - Glick Eye Institute /ID# 235886 — Indianapolis, Indiana, United States
• Retina Partners Midwest, PC /ID# 237876 — Indianapolis, Indiana, United States
• Tulane University School of Medicine /ID# 237632 — New Orleans, Louisiana, United States
• Ophthalmic Consultants of Boston /ID# 236534 — Boston, Massachusetts, United States
• Clinical Eye Research of Boston LLC /ID# 234966 — Winchester, Massachusetts, United States
• University of Michigan, Kellogg Eye Center /ID# 236496 — Ann Arbor, Michigan, United States
• Fraser Eye Center /ID# 235790 — Fraser, Michigan, United States
• Silverstein Eye Centers /ID# 237881 — Kansas City, Missouri, United States
• Moyes Eye Centers /ID# 234989 — Kansas City, Missouri, United States
• Alterman Modi & Wolter /ID# 235248 — Poughkeepsie, New York, United States
• The Ohio State University /ID# 236790 — Columbus, Ohio, United States
• AMA Eyes Research Institute /ID# 235542 — Marysville, Ohio, United States
• Dean McGee Eye Institute /ID# 236823 — Oklahoma City, Oklahoma, United States
• Horizon Eye Specialists & Lasik Centers /ID# 235240 — Sun City, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.